Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.31 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5859113 | 0.85 | PTGS2 (0.30) | — | |
| SCHEMBL5836794 | 0.85 | — | — | |
| SCHEMBL6032657 | 0.84 | BRD4 (0.30) | BRD4CREBBP | |
| SCHEMBL5859348 | 0.83 | CHRNB2 (0.33) | BRD4 | |
| SCHEMBL5860437 | 0.82 | RXRA (0.32) | — | |
| SCHEMBL5862311 | 0.81 | BRD9 (0.34) | BRD9BRD7BRD4CREBBP | |
| SCHEMBL1801597 | 0.77 | BRD4 (0.33) | BRD4CREBBP | |
| SCHEMBL5837498 | 0.77 | — | — | |
| SCHEMBL5859289 | 0.77 | BRD9 (0.31) | BRD9BRD7BRD4CREBBP | |
| SCHEMBL5860083 | 0.77 | METAP2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7081543-B2 | Bridged biscyclopentadienyl ligands and method of preparation | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2006-07-25 | — | — | US | claimed |
| US-20050250956-A1 | Bridged biscyclopentadienyl ligands and method of preparation | RIX FRANCIS C | 2005-11-10 | — | — | US | claimed |
| US-6960676-B2 | Method of preparing group 14 bridged biscyclopentadienyl ligands | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2005-11-01 | — | — | US | claimed |
| EP-1263764-B1 | METHOD OF PREPARING GROUP 14 BRIDGED BISCYCLOPENTADIENYL LIGANDS | EXXONMOBIL CHEM PATENTS INC (US) | 2004-04-14 | — | — | EP | claimed |
| US-20030220190-A1 | Method of preparing group 14 bridged biscyclopentadienyl ligands | EXXONMOBIL CHEMICAL PATENTS INC. | 2003-11-27 | — | — | US | claimed |
| EP-1263764-A1 | METHOD OF PREPARING GROUP 14 BRIDGED BISCYCLOPENTADIENYL LIGANDS | ExxonMobil Chemical Patents Inc. (US) | 2002-12-11 | — | — | EP | claimed |
| WO-2001058913-A1 | METHOD OF PREPARING GROUP 14 BRIDGED BISCYCLOPENTADIENYL LIGANDS | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2001-08-16 | — | — | WO | claimed |
| US-7081543-B2 | Bridged biscyclopentadienyl ligands and method of preparation | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2006-07-25 | — | — | US | disclosed |
| US-20050250956-A1 | Bridged biscyclopentadienyl ligands and method of preparation | RIX FRANCIS C | 2005-11-10 | — | — | US | disclosed |
| US-6960676-B2 | Method of preparing group 14 bridged biscyclopentadienyl ligands | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2005-11-01 | — | — | US | disclosed |
| EP-1263764-B1 | METHOD OF PREPARING GROUP 14 BRIDGED BISCYCLOPENTADIENYL LIGANDS | EXXONMOBIL CHEM PATENTS INC (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030220190-A1 | Method of preparing group 14 bridged biscyclopentadienyl ligands | EXXONMOBIL CHEMICAL PATENTS INC. | 2003-11-27 | — | — | US | disclosed |
| EP-1263764-A1 | METHOD OF PREPARING GROUP 14 BRIDGED BISCYCLOPENTADIENYL LIGANDS | ExxonMobil Chemical Patents Inc. (US) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001058913-A1 | METHOD OF PREPARING GROUP 14 BRIDGED BISCYCLOPENTADIENYL LIGANDS | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250956-A1 | Bridged biscyclopentadienyl ligands and method of preparation | FDPS, PPIP5K2, DBF4 | BRD9 428/4885BRD7 391/4885BRD4 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.